C330011K17Rik Inhibitors
Chemical inhibitors of C330011K17Rik can affect the protein's activity by targeting various signaling pathways and kinases that are crucial for its function. Staurosporine, as a pan-kinase inhibitor, can inhibit a wide range of kinases, which could include those that phosphorylate C330011K17Rik, leading to reduced protein activity. Similarly, Bisindolylmaleimide, by specifically inhibiting protein kinase C, can impact the activity of C330011K17Rik if PKC is involved in the protein's activation or regulation. LY294002 and Wortmannin both act as PI3K inhibitors; their inhibition of PI3K can decrease AKT phosphorylation, which may be essential for C330011K17Rik's function, resulting in lower activity of the protein.
Further, PD98059 and U0126 target MEK1/2 in the MAPK pathway; if C330011K17Rik is regulated by this pathway, inhibiting MEK would lead to decreased ERK activity and consequently lower C330011K17Rik activity. SP600125's inhibition of JNK signaling can similarly lead to a reduction in C330011K17Rik's activity if JNK is part of its regulatory mechanism. SB203580, which inhibits p38 MAP kinase, and Rapamycin, an mTOR inhibitor, can also reduce the function of proteins regulated by these pathways, including C330011K17Rik. PP2 selectively inhibits Src family kinases, and its use can lead to decreased C330011K17Rik activity if Src signaling regulates the protein. NF449, by inhibiting the Gs-alpha subunit of G proteins, can affect the signaling pathways involving C330011K17Rik. Lastly, Y-27632 inhibits ROCK kinase, which, if involved in the function of C330011K17Rik, would result in decreased activity of the protein upon inhibition. Each of these inhibitors acts by interfering with specific pathways and kinases that can modulate the function of C330011K17Rik, leading to a comprehensive approach to understanding the regulation of this protein's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent pan-kinase inhibitor that can inhibit multiple kinases involved in various signaling pathways. By inhibiting kinases that phosphorylate C330011K17Rik, it can reduce the protein's activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide is a specific inhibitor of protein kinase C (PKC). If PKC is involved in the activation or stabilization of C330011K17Rik, inhibiting PKC would result in the functional inhibition of C330011K17Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K. Inhibition of PI3K can lead to a decrease in AKT phosphorylation, which may be crucial for the function of C330011K17Rik, thereby inhibiting the protein's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor which, by inhibiting AKT activation, could reduce the phosphorylation and subsequent activity of proteins like C330011K17Rik that are downstream in the PI3K/AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. If C330011K17Rik is regulated by the MAPK pathway, inhibition of MEK would lead to decreased ERK activity and thus inhibit C330011K17Rik activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. If C330011K17Rik is activated or stabilized by JNK signaling, inhibition of JNK would result in functional inhibition of C330011K17Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Inhibiting p38 MAP kinase could lead to reduced function of proteins regulated by this pathway, potentially including C330011K17Rik, thus functionally inhibiting it. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which plays a key role in protein synthesis and cell growth. Inhibition of mTOR can lead to reduced activity of proteins regulated by this pathway, possibly including C330011K17Rik, thereby inhibiting its function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. If C330011K17Rik is regulated through Src kinase signaling, inhibition of this pathway by PP2 would result in functional inhibition of C330011K17Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. Inhibition of MEK1/2 and subsequent reduction in ERK activity could lead to inhibition of downstream proteins like C330011K17Rik. | ||||||